神経内分泌がん治療の世界市場 2020年：企業別、地域別、種類・用途別

• 英文タイトル：Global Neuroendocrine Carcinoma Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025

• レポートコード：D0804-16160 • 出版社/出版日：GlobalInfoResearch / 2020年7月28日 ※2025年版があります。お問い合わせください。 • レポート形態：英語、PDF、107ページ • 納品方法：Eメール • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査レポートでは、神経内分泌がん治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経内分泌がん治療の種類別市場規模（ソマトスタチン類似体、標的療法、化学療法）、用途別市場規模（病院、クリニック、腫瘍センター、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Pfizer、Teva Pharmaceutical Industries Ltd.、Ipsen、Novartis、Jubilant、Chiasma, Inc.、Mateon、Bausch Health、AbbVie、Roche ・地域別グローバル市場分析 2015年-2020年 ・神経内分泌がん治療の北米市場（アメリカ、カナダ、メキシコ） ・神経内分泌がん治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・神経内分泌がん治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・神経内分泌がん治療の南米市場（ブラジル、アルゼンチン） ・神経内分泌がん治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ソマトスタチン類似体、標的療法、化学療法 ・用途別分析：病院、クリニック、腫瘍センター、外来手術センター、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論

Market Overview
The global Neuroendocrine Carcinoma Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Neuroendocrine Carcinoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Neuroendocrine Carcinoma Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Neuroendocrine Carcinoma Treatment market has been segmented into:
Somatostatin Analogs
Targeted Therapy
Chemotherapy

By Application, Neuroendocrine Carcinoma Treatment has been segmented into:
Hospitals
Clinics
Oncology Centers
Ambulatory Surgical Centers
Others

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuroendocrine Carcinoma Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuroendocrine Carcinoma Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuroendocrine Carcinoma Treatment market.

The report offers in-depth assessment of the growth and other aspects of the Neuroendocrine Carcinoma Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Neuroendocrine Carcinoma Treatment Market Share Analysis
Neuroendocrine Carcinoma Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuroendocrine Carcinoma Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuroendocrine Carcinoma Treatment sales, revenue and market share for each player covered in this report.

The major players covered in Neuroendocrine Carcinoma Treatment are:
Pfizer
Teva Pharmaceutical Industries Ltd.
Ipsen
Novartis
Jubilant
Chiasma, Inc.
Mateon
Bausch Health
AbbVie
Roche

レポート目次

---

Table of Contents

1 Neuroendocrine Carcinoma Treatment Market Overview
1.1 Product Overview and Scope of Neuroendocrine Carcinoma Treatment
1.2 Classification of Neuroendocrine Carcinoma Treatment by Type
1.2.1 Global Neuroendocrine Carcinoma Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type in 2019
1.2.3 Somatostatin Analogs
1.2.4 Targeted Therapy
1.2.5 Chemotherapy
1.3 Global Neuroendocrine Carcinoma Treatment Market by Application
1.3.1 Overview: Global Neuroendocrine Carcinoma Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Oncology Centers
1.3.5 Ambulatory Surgical Centers
1.3.6 Others
1.4 Global Neuroendocrine Carcinoma Treatment Market by Regions
1.4.1 Global Neuroendocrine Carcinoma Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Neuroendocrine Carcinoma Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Neuroendocrine Carcinoma Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Neuroendocrine Carcinoma Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Neuroendocrine Carcinoma Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Neuroendocrine Carcinoma Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Neuroendocrine Carcinoma Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Pfizer SWOT Analysis
2.1.4 Pfizer Product and Services
2.1.5 Pfizer Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Teva Pharmaceutical Industries Ltd.
2.2.1 Teva Pharmaceutical Industries Ltd. Details
2.2.2 Teva Pharmaceutical Industries Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Teva Pharmaceutical Industries Ltd. SWOT Analysis
2.2.4 Teva Pharmaceutical Industries Ltd. Product and Services
2.2.5 Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 Ipsen
2.3.1 Ipsen Details
2.3.2 Ipsen Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Ipsen SWOT Analysis
2.3.4 Ipsen Product and Services
2.3.5 Ipsen Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Novartis SWOT Analysis
2.4.4 Novartis Product and Services
2.4.5 Novartis Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Jubilant
2.5.1 Jubilant Details
2.5.2 Jubilant Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Jubilant SWOT Analysis
2.5.4 Jubilant Product and Services
2.5.5 Jubilant Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Chiasma, Inc.
2.6.1 Chiasma, Inc. Details
2.6.2 Chiasma, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Chiasma, Inc. SWOT Analysis
2.6.4 Chiasma, Inc. Product and Services
2.6.5 Chiasma, Inc. Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Mateon
2.7.1 Mateon Details
2.7.2 Mateon Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Mateon SWOT Analysis
2.7.4 Mateon Product and Services
2.7.5 Mateon Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Bausch Health
2.8.1 Bausch Health Details
2.8.2 Bausch Health Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Bausch Health SWOT Analysis
2.8.4 Bausch Health Product and Services
2.8.5 Bausch Health Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 AbbVie
2.9.1 AbbVie Details
2.9.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 AbbVie SWOT Analysis
2.9.4 AbbVie Product and Services
2.9.5 AbbVie Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Roche SWOT Analysis
2.10.4 Roche Product and Services
2.10.5 Roche Neuroendocrine Carcinoma Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Neuroendocrine Carcinoma Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Neuroendocrine Carcinoma Treatment Players Market Share
3.2.2 Top 10 Neuroendocrine Carcinoma Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Neuroendocrine Carcinoma Treatment Revenue and Market Share by Regions
4.2 North America Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
5 North America Neuroendocrine Carcinoma Treatment Revenue by Countries
5.1 North America Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
5.2 USA Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
6 Europe Neuroendocrine Carcinoma Treatment Revenue by Countries
6.1 Europe Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
6.2 Germany Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
6.4 France Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue by Countries
7.1 Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
7.2 China Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
7.5 India Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
8 South America Neuroendocrine Carcinoma Treatment Revenue by Countries
8.1 South America Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
8.2 Brazil Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Neuroendocrine Carcinoma Treatment by Countries
9.1 Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Neuroendocrine Carcinoma Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Neuroendocrine Carcinoma Treatment Market Forecast by Type (2019-2024)
10.3 Somatostatin Analogs Revenue Growth Rate (2015-2025)
10.4 Targeted Therapy Revenue Growth Rate (2015-2025)
10.5 Chemotherapy Revenue Growth Rate (2015-2025)
11 Global Neuroendocrine Carcinoma Treatment Market Segment by Application
11.1 Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Application (2015-2020)
11.2 Neuroendocrine Carcinoma Treatment Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Oncology Centers Revenue Growth (2015-2020)
11.6 Ambulatory Surgical Centers Revenue Growth (2015-2020)
11.7 Others Revenue Growth (2015-2020)
12 Global Neuroendocrine Carcinoma Treatment Market Size Forecast (2021-2025)
12.1 Global Neuroendocrine Carcinoma Treatment Market Size Forecast (2021-2025)
12.2 Global Neuroendocrine Carcinoma Treatment Market Forecast by Regions (2021-2025)
12.3 North America Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
12.6 South America Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Neuroendocrine Carcinoma Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuroendocrine Carcinoma Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuroendocrine Carcinoma Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Neuroendocrine Carcinoma Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Pfizer Corporate Information, Location and Competitors
Table 6. Pfizer Neuroendocrine Carcinoma Treatment Major Business
Table 7. Pfizer Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Pfizer SWOT Analysis
Table 9. Pfizer Neuroendocrine Carcinoma Treatment Product and Solutions
Table 10. Pfizer Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Teva Pharmaceutical Industries Ltd. Corporate Information, Location and Competitors
Table 12. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Major Business
Table 13. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Teva Pharmaceutical Industries Ltd. SWOT Analysis
Table 15. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Product and Solutions
Table 16. Teva Pharmaceutical Industries Ltd. Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Ipsen Corporate Information, Location and Competitors
Table 18. Ipsen Neuroendocrine Carcinoma Treatment Major Business
Table 19. Ipsen Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 20. Ipsen SWOT Analysis
Table 21. Ipsen Neuroendocrine Carcinoma Treatment Product and Solutions
Table 22. Ipsen Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Novartis Corporate Information, Location and Competitors
Table 24. Novartis Neuroendocrine Carcinoma Treatment Major Business
Table 25. Novartis Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 26. Novartis SWOT Analysis
Table 27. Novartis Neuroendocrine Carcinoma Treatment Product and Solutions
Table 28. Novartis Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Jubilant Corporate Information, Location and Competitors
Table 30. Jubilant Neuroendocrine Carcinoma Treatment Major Business
Table 31. Jubilant Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Jubilant SWOT Analysis
Table 33. Jubilant Neuroendocrine Carcinoma Treatment Product and Solutions
Table 34. Jubilant Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Chiasma, Inc. Corporate Information, Location and Competitors
Table 36. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Major Business
Table 37. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Chiasma, Inc. SWOT Analysis
Table 39. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Product and Solutions
Table 40. Chiasma, Inc. Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Mateon Corporate Information, Location and Competitors
Table 42. Mateon Neuroendocrine Carcinoma Treatment Major Business
Table 43. Mateon Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Mateon SWOT Analysis
Table 45. Mateon Neuroendocrine Carcinoma Treatment Product and Solutions
Table 46. Mateon Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Bausch Health Corporate Information, Location and Competitors
Table 48. Bausch Health Neuroendocrine Carcinoma Treatment Major Business
Table 49. Bausch Health Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Bausch Health SWOT Analysis
Table 51. Bausch Health Neuroendocrine Carcinoma Treatment Product and Solutions
Table 52. Bausch Health Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. AbbVie Corporate Information, Location and Competitors
Table 54. AbbVie Neuroendocrine Carcinoma Treatment Major Business
Table 55. AbbVie Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 56. AbbVie SWOT Analysis
Table 57. AbbVie Neuroendocrine Carcinoma Treatment Product and Solutions
Table 58. AbbVie Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Roche Corporate Information, Location and Competitors
Table 60. Roche Neuroendocrine Carcinoma Treatment Major Business
Table 61. Roche Neuroendocrine Carcinoma Treatment Total Revenue (USD Million) (2017-2018)
Table 62. Roche SWOT Analysis
Table 63. Roche Neuroendocrine Carcinoma Treatment Product and Solutions
Table 64. Roche Neuroendocrine Carcinoma Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Players (2015-2020)
Table 66. Global Neuroendocrine Carcinoma Treatment Revenue Share by Players (2015-2020)
Table 67. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Regions (2015-2020)
Table 68. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Regions (2015-2020)
Table 69. North America Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
Table 70. North America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Europe Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 72. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 73. South America Neuroendocrine Carcinoma Treatment Revenue by Countries (2015-2020)
Table 74. South America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Table 75. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Countries (2015-2020)
Table 76. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Table 77. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) by Type (2015-2020)
Table 78. Global Neuroendocrine Carcinoma Treatment Revenue Share by Type (2015-2020)
Table 79. Global Neuroendocrine Carcinoma Treatment Revenue Forecast by Type (2021-2025)
Table 80. Global Neuroendocrine Carcinoma Treatment Revenue by Application (2015-2020)
Table 81. Global Neuroendocrine Carcinoma Treatment Revenue Share by Application (2015-2020)
Table 82. Global Neuroendocrine Carcinoma Treatment Revenue Forecast by Application (2021-2025)
Table 83. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Neuroendocrine Carcinoma Treatment Picture
Figure 2. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Type in 2019
Figure 3. Somatostatin Analogs Picture
Figure 4. Targeted Therapy Picture
Figure 5. Chemotherapy Picture
Figure 6. Neuroendocrine Carcinoma Treatment Revenue Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Oncology Centers Picture
Figure 10. Ambulatory Surgical Centers Picture
Figure 11. Others Picture
Figure 12. Global Neuroendocrine Carcinoma Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Neuroendocrine Carcinoma Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Neuroendocrine Carcinoma Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Neuroendocrine Carcinoma Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Neuroendocrine Carcinoma Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries in 2019
Figure 45. China Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Neuroendocrine Carcinoma Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Neuroendocrine Carcinoma Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Neuroendocrine Carcinoma Treatment Revenue Share by Type in 2019
Figure 62. Global Neuroendocrine Carcinoma Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Somatostatin Analogs Revenue Growth Rate (2015-2020)
Figure 64. Global Targeted Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 66. Global Neuroendocrine Carcinoma Treatment Revenue Share by Application (2015-2020)
Figure 67. Global Neuroendocrine Carcinoma Treatment Revenue Share by Application in 2019
Figure 68. Global Neuroendocrine Carcinoma Treatment Market Share Forecast by Application (2021-2025)
Figure 69. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 70. Global Clinics Revenue Growth Rate (2015-2020)
Figure 71. Global Oncology Centers Revenue Growth Rate (2015-2020)
Figure 72. Global Ambulatory Surgical Centers Revenue Growth Rate (2015-2020)
Figure 73. Global Others Revenue Growth Rate (2015-2020)
Figure 74. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Neuroendocrine Carcinoma Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Neuroendocrine Carcinoma Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Neuroendocrine Carcinoma Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel

---